A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.

"data are available on the ncbi geo repository ( gse135251 ). data availability rna-seq data are available on the ncbi geo repository ( https://www ncbi nlm nih gov/geo/query/acc cgi? acc=gse135251"

"Competing interests O.G. reports grants from NanoString Technologies. L.A. is employed by SomaLogic, Inc. D.T. reports consultation fees from Histoindex Pte Ltd. M.E. is a member of the advisory board at AMRA Medical AB. J.M.S. reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Genfit, Gilead Sciences, GSK, Heel GmbH, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Julius Clinical, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shinogi, Siemens Healthcare GmbH and Summit Clinical Research; research funding from Gilead Sciences, Boehringer Ingelheim, Nordic Bioscience and Siemens Healthcare GmbH; and speaker honoraria from MedPublico GmbH and Boehringer Ingelheim, all outside of the submitted work. J.B. consults for and received grants from Echosens and Siemens. E.B. served as a consultant or advisory board member for Boehringer Ingelheim, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, ProSciento and a speaker for Gilead Sciences, MSD and Novo Nordisk, outside of the submitted work. Q.M.A. reports grants from European Commission during the conduct of the study; other grants from AstraZeneca, Boehringer Ingelheim, Intercept; consultancy for Alimentiv, Akero, AstraZeneca, Axcella, 89Bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Prosciento, Poxel, Resolution Therapeutics, Roche, Ridgeline Therapeutics, RTI, Shionogi, Terns. The remaining authors declare no competing interests."

"This study has been supported by the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under grant agreement no. 777377, which receives funding from the EU Horizon 2020 programme and EFPIA; the Elucidating Pathways of Steatohepatitis consortium funded by the Horizon 2020 Framework Program of the European Union under grant agreement no. 634413; the European NAFLD Registry and the Newcastle National Institute for Health and Care Research Biomedical Research Centre. Q.M.A. is a National Institute of Health and Care Research Senior Investigator."